Skip to content
ClinCalc Pro
Menu
Low Molecular Weight Heparin (LMWH) — VTE Prophylaxis/Treatment

Enoxaparin (VTE in Pregnancy)

Brand names: Clexane

Enoxaparin is a low molecular weight heparin used in pregnancy for prophylaxis and treatment of venous thromboembolism and as the anticoagulant of choice in this setting.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Potentiates antithrombin to inhibit factor Xa (and to a lesser extent thrombin), reducing thrombin generation and clot propagation.

Prescribing in practice

  • Low molecular weight heparin is the preferred anticoagulant in pregnancy because, unlike warfarin and direct oral anticoagulants, it does not cross the placenta and avoids fetal harm.
  • Dosing is weight-based and should be adjusted as maternal weight changes; renal impairment requires caution and reduced exposure.
  • Plan timing of doses around delivery and regional anaesthesia to limit bleeding and spinal haematoma risk, in line with obstetric anaesthetic guidance.

Monitoring

Routine anti-Xa monitoring is not needed for most patients but is considered at extremes of body weight or in significant renal impairment, alongside platelet awareness.

Counselling the patient

  • Learn the subcutaneous injection technique and rotate sites; some bruising at the site is common.
  • Report unusual bleeding, and stop dosing and contact the maternity team when labour begins as advised.
  • Do not miss doses, as continued prophylaxis is important throughout the agreed period including after delivery.

Evidence & guidelines

RCOG guidance recommends low molecular weight heparin for the prevention and treatment of venous thromboembolism in pregnancy and the puerperium.

Reference: RCOG Green-top 37a VTE in Pregnancy; NICE NG89; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.